US FDA rejects antibiotic non-inferiority studies for bronchitis
This article was originally published in Scrip
A new US FDAdraft guideline formally rejects the use of non-inferiority studies in the development of antimicrobial drugs for acute bacterial exacerbations of chronic bronchitis (ABECB), making clear that only superiority trials are recommended. The document stresses the importance of clinical benefit as an outcome and relies heavily on the use of patient-reported measures in assessing efficacy.
You may also be interested in...
Timelines in the CID program are tight, and sponsors should have a ‘fully baked’ trial design before heading into their first meeting with the agency, industry reps say; agency needs more simulation data from participating sponsors earlier and is working to ensure continuity for firms after the second of two meetings allowed under the program.
Oncology Center of Excellence’s Paul Kluetz says agency intends to explore the effects of decentralization, remote assessments and other approaches adopted mid-stream on safety evaluations, missing data and endpoint variability.
Work on guidance that was originally expected in 2020 continues as the agency and industry learn more about the utility and spectrum of decentralized trials as a result of the novel coronavirus pandemic.